Overall, abnormalities in m6A-related factors, represented by METTL3 and METTL14, may be potential factors in the development of hematologic malignancies (e.g., AML), which provide a novel research direction for their clinical diagnosis and treatment. Here, METTL3 is linked to acute myeloid leukemia.